Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"In community settings, the most common barriers to independent living, employment, and stable interpersonal relationships for patients suffering from schizophrenia-spectrum disorders or other psychotic disorders are negative symptoms and cognitive deficits. In contrast, severely mentally ill individuals, often incarcerated or chronically institutionalized, more frequently experience substantial barriers related to positive psychotic symptoms leading to problematic behaviors such as aggression or violence. This is not to say that among the chronically institutionalized severely mentally ill population that positive psychotic symptoms are the only, or even majority, source of problematic behaviors. A survey conducted within the California Department of State Hospitals, a circa 7000-bed system dedicated to the treatment of conserved and forensically committed patients, reviewed 839 episodes of aggression or violence by 88 persistently aggressive inpatients and found that 54% of such episodes were impulsive, 39% were predatory or instrumental, and 17% were psychotically driven. Nevertheless, amelioration or control of positive psychotic symptoms commonly forms the initial treatment focus among the severely mentally ill."--

Psychotic Disorders --- Antipsychotic Agents --- Psychopharmacology --- Drug Resistance

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Outside back cover : "Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole has recently been approved for clinical use in the United States and is likely to be approved in Europe soon. The second edition of this successful book has been fully updated to include this new data, with reference to both observational studies and randomized controlled trials, as well as other new developments in the clinical use of antipsychotic LAIs. New chapters have been added covering the comparison between oral and injectable antipsychotics, Olanzapine LAI, Aripiprazole LAI, and the practicalities of organizing a specialized clinic for long-acting injectable antipsychotics. Existing chapters have also been thoroughly updated to take into account the most recently published research. Antipsychotic Long-acting Injections, Second edition brings together clinical and research findings on LAIs in a comprehensive volume, with chapters written by international experts.

Antipsychotic drugs --- Injections --- Antipsychotic Agents --- Delayed-Action Preparations --- Injections

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antipsychotic drugs --- Antipsychotic Agents --- Schizophrenia --- Testing --- therapeutic use --- drug therapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

NEUROPEPTIDES --- IMMUNOLOGY --- REGULATION --- CHOLECYSTOKININ --- DOPAMINE --- NEUROTENSIN --- FLUOROQUINOLONES --- QUINOLONES --- ANTIPSYCHOTIC AGENTS --- CLOZAPINE --- I.M.A.O. --- REGULATION --- NEUROPEPTIDES --- IMMUNOLOGY --- REGULATION --- CHOLECYSTOKININ --- DOPAMINE --- NEUROTENSIN --- FLUOROQUINOLONES --- QUINOLONES --- ANTIPSYCHOTIC AGENTS --- CLOZAPINE --- I.M.A.O. --- REGULATION

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antipsychotic Agents --- Anxiety Disorders --- Pharmaceutical Preparations --- Tranquilizing drugs --- Antipsychotic drugs --- Tranquillisants --- Neuroleptiques --- history --- drug therapy --- history --- History. --- History. --- Histoire --- Histoire